Safety and Efficacy Study of Avastin in Locally Advanced Metastatic or Recurrent Non-small Lung Cancer (NSLC) Participants

Roche

Status: Completed

Conditions: Non-Squamous Non-Small Cell Lung Cancer

Treatments: Drug: Bevacizumab

Study type: Observational

Funder types: Industry

Identifiers

NCT02596958

ML21217

Details and patient eligibility

About

The purpose of this non-interventional study is the collection and documentation of data on safety and efficacy of intravenous (IV) bevacizumab (Avastin) in addition to platinum-based chemotherapy for first-line treatment in participants with unresectable advanced, metastatic or recurrent non-small cell lung cancer (NSCLC) other than predominantly squamous cell histology with focus on adenocarcinoma and elderly patients in daily routine.

Enrollment: 996 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age greater than or equal to (>=) 18 years
• Histologically confirmed predominantly non-squamous NSCLC that is unresectably advanced, metastatic or recurrent (with or without adenocarcinoma)
• No contraindications to Avastin® according to the current Summary of Product Characteristics (SmPC) for Avastin®
• Therapeutic decision for Avastin® as first line treatment in combination with platinum-based chemotherapy was taken individually and independent of the non-interventional trial.

Exclusion criteria

N/A

Trial design

996 participants in 1 patient group

Bevacizumab

Description:

Patients will receive six 3-weeks cycle of IV bevacizumab along with platinum-based chemotherapy, followed by maintenance therapy of bevacizumab until progression (approximately 7 months).

Treatment:

Drug: Bevacizumab